Based on six DC marker genes (CCDC50, ETV5, LAMP5, NEURL3, SDS, CR2), we constructed a robust prognostic feature set that can reliably predict the prognosis and efficacy of immunotherapy in ESCC. This evidence concerns the gene NEURL3 and esophageal squamous cell carcinoma.